Skip to main content

Table 5 NCI60 cell lines with predicted active pathways by mutational analysis

From: Data recovery and integration from public databases uncovers transformation-specific transcriptional downregulation of cAMP-PKA pathway-encoding genes

Tumor Type Ras PI3K Other Mutation Not Tested
Breast HS578T, MDA-MB231, MD-MB435 MCF7, T47, - MDA-N, BT549
CNS - SF295, SF359, SNB19, U251 SF268, SNB75 -
Colon HCC2998, HCT116, HCT15, SW620, COLO205, HT29 KM12 - -
Leukaemia CCRF-CEM, RPMI-8226, HL60, MOLT4, K562 - - SR
Melanoma SK-MEL2, LOXIMVI, M14, MALME-3M, SK-MEL28, SK-MEL5, UACC257, UACC62 - - -
Lung A549, HOP62, NCI-H23, NCI-H460 - EKVX, NCI-H226, NCI-H322, NCI-H522 HOP92
Ovarian OVCAR5, OVCAR8 SKOW3, IGROV1 OVCAR3, OVCAR4 -
Prostate - PC3, DU145 - -
Renal - 786-0, RXF-393 A498, ACHN, CAKI-1, SNC12C, TK10, U031 -
Unknown ADR-RES - - -
  1. The 60 cell lines reorganized in 4 categories, as described in the text, on the basis of the most representative mutation of each cell line:
  2. Cell lines carrying mutations able to interfere with Ras-Raf-MAPK pathway (i.e., mutations in genes encoding Ras, B-Raf, ERBB2, PDGFRA, referred to as Ras);
  3. Cell lines carrying mutations able to interfere with PI3K-Akt pathway (i.e., mutations in genes encoding PI3KCA, PTEN and Lkb1, referred to as PI3K);
  4. Cell lines carrying no somatic mutations interfering with the two above pathways (i.e., mutations in genes encoding for CDKN2A, p53, referred to as Other Mutation);
  5. Cell lines for which the presence of somatic mutations interfering with the two above pathways has not been searched, referred to as Not Tested.